NCT04811261View on ClinicalTrials.gov

u-STOP LVAD Bleed: Utilization of Umbilical Cord Lining Stem Cells (ULSCs) To Prevent Left Ventricular Assist Device (LVAD) Associated Angiodysplastic Bleeding

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

July 27, 2023

Study Completion Date

July 27, 2023

Conditions
Angiodysplastic Bleeding
Interventions
DRUG

Intravenous Infusion of UCLSCs

The first 3 subjects will be administered 50 x 10\^6 ULSCs reconstituted in PBS with 1% human serum albumin in a volume of 250 ml, and monitored for adverse events or toxicities, immediately following dosing, and again at 30 days.

Trial Locations (1)

32610

University of Florida, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER

NCT04811261 - u-STOP LVAD Bleed: Utilization of Umbilical Cord Lining Stem Cells (ULSCs) To Prevent Left Ventricular Assist Device (LVAD) Associated Angiodysplastic Bleeding | Biotech Hunter | Biotech Hunter